• Skip to Content
  • Skip to Sidebar
IU

Indiana University Indiana University IU

Innovate IndianaNews and information on how IU is driving innovation, entrepreneurship and economic development

IU researcher develops new therapy for treatment of ALS

Posted on February 2, 2023 by Ryan Piurek

Bri Heron, technology marketing manager at Indiana University’s Innovation and Commercialization Office, contributed the following story.

Indiana University researcher Chandler Walker, Ph.D., has developed a new stem cell-based secretome therapy that influences both the central and peripheral components of Amyotrophic Lateral Sclerosis pathology. Secretome refers to the secretions of tissue or cells that can be harvested for therapeutic or other purposes.

One in 50,000 people has ALS, a rare neurodegenerative disease that primarily affects the nerve cells that control voluntary muscle movement and causes the gradual degeneration and death of upper and lower motor neurons in the central nervous system. Death of motor neurons is a hallmark of ALS, but other cells in the brain and spinal cord, as well as peripheral myelinating cells and skeletal muscle, all play a role in disease progression.

Chandler Walker
Chandler Walker

The average survival time after diagnosis of ALS is three to five years, and there is currently no cure or treatment to stop or reverse disease progression. While a few FDA-approved drugs provide marginal therapeutic benefits for patients, they primarily only target the central nervous system while the peripheral nervous system continues to degenerate.

“Getting an effective therapy to people with ALS sooner than later is our top priority,” said Walker, an associate professor at the IU School of Dentistry and adjunct associate professor of anatomy, cell biology and physiology at the IU School of Medicine. Given the rapid progression of ALS, time is of utmost concern for afflicted individuals, their families and caretakers. With the limited efficacy of current approved treatments, having a new therapy that could slow disease progression and prolong life would positively affect thousands of individuals in the United States alone.

Walker’s research, published in Neural Regeneration Research, has shown therapeutic benefits at various stages of disease progression in an ALS mouse model. Administering the treatment delayed symptom progression, reduced neuromuscular degeneration and extended survival time. Daily systemic administration of the therapy allows for targeting of both central and peripheral characteristics of disease progression. This approach sheds light on the effects of the treatment on specific types of disease pathology as well as the long-term therapeutic benefits of adipose-derived stem cell (ASC) secretome therapy.

“For neural disorders and diseases like ALS, a multi-factorial approach to therapy is the most beneficial for patients,” Walker said. As ALS negatively affects neurons in the brain and spinal cord, as well as peripheral tissues such as skeletal muscle and immune cells, targeting just one organ or set of tissues is insufficient for meaningly impacting disease progression. Walker’s ASC secretome therapy contains hundreds of growth factors and other pro-regenerative and protective components that affect the wide range of areas of the body impacted by ALS. Furthermore, neurological conditions other than ALS also involve central and peripheral pathologies. “This secretome therapy could also have a therapeutic affect for other neurodegenerative diseases such as Alzheimer’s or Parkinson’s,” he said.

Chandler Walker working in his lab.
Given the limited efficacy of current approved treatments for ALS, Walker’s newly developed stem-cell-based therapy, which has shown therapeutic benefits at various stages of the disease’s progression, could positively affect thousands of individuals in the United States alone.

Walker and his team will continue their studies on the therapeutic composition of the secretome, hoping to eventually produce a clinic-ready therapy for ALS patients, thanks to $700,000 in funding from Neurodegenerative Disease Research, a nonprofit organization supporting researchers studying disease pathology and therapeutic development in ALS.

Walker has also partnered with IU School of Medicine’s Cell and Gene Therapy Manufacturing Center to optimize and produce ASC secretome for FDA approval and a Phase I clinical trial. He is optimistic that the team will have clinical-grade ASC secretome ready for clinical application in the next six to 12 months.

Walker has worked with the Innovation and Commercialization Office for a couple of other inventions, and he participated in ICO’s IU Idea to Startup Pitch Competition last October.

“I am thankful that I was able to participate in the pitch competition as it showed me a different way of presenting my ALS research,” Walker said. “I am able to apply what I learn from ICO along with the feedback from the competition to move our secretome therapy closer to the patients that need it.”

Share this:

  • Click to share on Facebook (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)

Filed under: Engagement, Entrepreneurship, Faculty, IU Innovation and Commercialization Office, Research, Statewide EngagementTagged ALS, Alzheimer's disease, Amyotrophic Lateral Sclerosis, Chandler Walker, IU Idea to Startup Pitch Competition, IU Innovation and Commercialization Office, IU School of Dentistry, IU School of Medicine, neural diseases, neural disorders, Neurodegenerative Disease Research, neurodegenerative diseases, new therapy, Parkinson's, stem cell research

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Additional Content

Innovate Indiana Button

Search Innovate Indiana

About Innovate Indiana

Join us as we highlight how IU innovation is accelerating economic growth in Indiana and beyond and creating a culture of entrepreneurship across the Hoosier state.

Innovate Indiana is maintained by the Indiana University Office of the Vice President for University Relations.

Recent Posts

  • Moving IU innovation to market to improve Hoosier health March 22, 2023
  • IU School of Medicine researcher develops a novel, highly efficient method of producing retinal organoids March 14, 2023
  • Strengthening civics education in Indiana and beyond March 10, 2023
  • Hoosier hoops great Alan Henderson set to bring his new venture game back to Bloomington March 8, 2023
  • IU School of Medicine researcher develops non-invasive tool to detect mutations that could potentially lead to breast cancer February 24, 2023

Categories

Bookmarks

  • Innovate Indiana website
  • IU Center on Representative Government
  • IU Impact
  • IU Innovation and Commercialization Office
  • IU Office of the Vice President for Research
  • IU Office of the Vice President for University Relations
  • IU Ventures

Subscribe to the Innovate Indiana blog

Opt out at any time.

Please, insert a valid email.

Thank you, your email will be added to the mailing list once you click on the link in the confirmation email.

Spam protection has stopped this request. Please contact site owner for help.

This form is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Indiana University

Copyright © 2022 The Trustees of Indiana University | Privacy Notice | Accessibility Help

Subscribe

Subscribe By Email

Get every new post delivered right to your inbox.

This form is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.